On October 12th we invited Clustermarket to come talk about cloud-based tools for R&D companies. Did you miss the webinar? No worries! Click the button below to watch it back! During his presentation, Clustermarket
London, 27th September 2021 - Kadans Science Partner has added Merlin Place, Cambridge, UK to its Pan-European portfolio. The asset was acquired from a private investor. This acquisition continues Kadans’ growth in Cambridge following
The search for renewable energy sources is gaining ground. Wind and solar energy have been familiar to us for quite some time, but there are countless other innovations that generate emission-free energy. The question
Date: Tuesday, October 12Programme:11.00 AM CEST : Presentation Clustermarket11.45 AM CEST : Q & AWhere: OnlineThis webinar is powered by: Clustermarket When managing an R&D facility, you have many responsibilities in order to have your
Kadans Science Partner welcomes global molecular diagnostics innovator, Sense Biodetection (Sense), to The Science Quadrant at Abingdon Science Park, Oxfordshire. The move doubles Sense’s existing laboratory capacity, enhancing the firm’s capability to accelerate development
Cancer is one of the world’s most devastating diseases. Its treatment can be punishing, and have several nasty side effects. Fortunately, scientists have a better idea now of how to treat it, and the
Online crime is now just as common and obvious as in the offline world: Ddos attacks, theft of personal data, phishing... and so on. But in our connected society, the stakes are often very
Building the Future episode 5: Your next doctor will be a robot If there is one area where technological developments are introduced at a rapid pace, it is the medical sector. A growing number
Louvain-la-Neuve, August 3, 2021 - Kadans Science Partner has expanded its portfolio with the acquisition of Watson & Crick Hill. By doing so, Kadans adds its first location in Belgium to its European portfolio.
AXA IM Alts has raised €1.9 billion of equity to accelerate investments into the Life Sciences sector. The capital raised will primarily be invested through Kadans Science Partner, which will enable Kadans to execute
